Recombinant Human VEGF121 Protein，His

Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis, playing a crucial role in both physiological and pathological processes, including wound healing, tumor growth, and retinal neovascularization. Among the various isoforms of VEGF, VEGF121 is notable for its potent angiogenic properties, as it lacks the heparin-binding domain, leading to its increased solubility and diffusion in tissues. This characteristic makes VEGF121 particularly interesting for therapeutic applications, especially in conditions where enhanced blood vessel formation is desired. Research has focused on the recombinant production of VEGF121 to explore its biological functions, optimize delivery methods, and evaluate its potential in regenerative medicine and cancer therapy. Furthermore, studies have demonstrated that VEGF121 can promote endothelial cell proliferation, migration, and survival, making it a candidate for interventions in ischemic diseases. However, the challenge remains to balance the angiogenic effects with potential adverse outcomes, such as edema or abnormal vessel formation. Thus, ongoing research aims to elucidate the molecular mechanisms of VEGF121 action and its therapeutic efficacy, paving the way for innovative treatments that harness the power of angiogenesis while mitigating associated risks.